Search Results
Jul 30, 2026, 09:10 ET NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut
data.Opening BellJersey Mike's (NYSE: JMKE) celebrates its IPOClosing BellBlackberry (NYSE: BB) celebrates its evolution into a company trusted in some of the world's most demanding environments.For market insights, IPO activity, and today's
More news about: New York Stock Exchange
Jul 30, 2026, 07:00 ET Basking Biosciences Announces Publication Showing BB-031 Restores Blood Flow in a Microfluidic Model of Acute Ischemic Stroke (AIS)
intervention, BB-025 can be administered to neutralize BB-031.About BB-025BB-025 is an investigational, rapid-acting oligonucleotide reversal agent that specifically binds to BB-031. Administered as a single intravenous bolus, BB-025 is designed to rapidly and durably reverse BB-031's thrombolytic
More news about: Basking Biosciences Inc.
Jul 30, 2026, 06:45 ET Life Time Reports Second Quarter 2026 Financial Results
letters of credit.On April 21, 2026, Fitch Ratings upgraded our issuer credit rating to 'BB' from 'BB-' and on June 25, 2026, S&P Global Ratings upgraded our issuer credit rating to 'BB' from 'BB-'.During the three months ended June 30, 2026, we repurchased approximately 2.2 million
More news about: Life Time Group Holdings, Inc.
Jul 29, 2026, 08:00 ET REPUBLIC OF URUGUAY - ANNOUNCEMENT OF GLOBAL TENDER OFFER RESULTS
US760942BB71760942 BB7131158840
More news about: The Republic of Uruguay
Jul 29, 2026, 07:30 ET M/I Homes Reports 2026 Second Quarter Results
ability to navigate this uncertain environment. Our financial condition is excellent, highlighted by S&P's recent upgrade of our credit rating to BB+. We have a very strong balance sheet with record shareholders' equity of $3.2 billion, no borrowings under our $900 million unsecured credit facility,
More news about: M/I Homes, Inc.
Jul 28, 2026, 11:36 ET 広州のHOPE & SESAMEがASIA'S 50 BEST BARS 2026でNO.1に輝く
https://mmx.prnewswire.com/media/MS1890898/A50BB2026-Results-The-List.pdf?id=OA2779256
More news about: 50 Best
Jul 28, 2026, 11:32 ET 광저우 HOPE & SESAME, ASIA'S 50 BEST BARS 2026에서 No.1 등극
https://mmx.prnewswire.com/media/MS1890898/A50BB2026-Results-The-List.pdf?id=OA2779256
More news about: 50 Best
Jul 28, 2026, 11:27 ET HOPE & SESAME TẠI QUẢNG CHÂU GIÀNH VỊ TRÍ NO.1 TẠI ASIA'S 50 BEST BARS 2026
https://mmx.prnewswire.com/media/MS1890898/A50BB2026-Results-The-List.pdf?id=OA2779256
More news about: 50 Best
Jul 28, 2026, 07:58 ET REPUBLIC OF URUGUAY - ANNOUNCEMENT OF TENDER OFFERS
US760942BB71760942 BB7131158840
More news about: The Republic of Uruguay
Jul 28, 2026, 03:37 ET Registration Now Open for the Mininglamp Technology WebRetriever Global Challenge--Win Your Share of the $15,000 Prize Pool!
Platform Octo：https://im.deepminer.com.cn/Space invite code: 0f351ca01bb4c4ddStep 1 — Create an Octo account (skip if you already have one)Option A: Sign up at the
More news about: Mininglamp Technology
Jul 27, 2026, 16:06 ET AllianceBernstein National Municipal Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
16.70 %BB8.01 %
More news about: AllianceBernstein National Municipal Income Fund, Inc.
Jul 27, 2026, 16:06 ET AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
15.31 %BB
More news about: AllianceBernstein Global High Income Fund, Inc.
Jul 27, 2026, 09:18 ET Precision Healthcare CFO Advisory Opens to Address the Profitability Gap in Dental Practices
[email protected], www.linkedin.com/in/dr-anthony-pedicino-bb58ab379
More news about: P.R.E.C.I.S.E. Profit System
Jul 23, 2026, 08:47 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
alpha, Trop2 and Her2 along with additional innovative oncology assets directed at important IO targets, including novel bispecific targeting PD-L1/4-1BB and PD1/IL15, all in early-stage clinical studies.About Bio-Thera SolutionsBio-Thera Solutions, Ltd., a leading innovative, global
More news about: Bio-Thera Solutions, Ltd
Jul 23, 2026, 07:00 ET Harley-Davidson Delivers Second Quarter Financial Results and Raises Full-Year Guidance
on the Company's business; (aa) manage through the effects inconsistent and unpredictable weather patterns may have on retail sales of motorcycles; (bb) implement and manage enterprise-wide information technology systems, including systems at its manufacturing facilities; (cc) manage changes, prepare
More news about: Harley-Davidson, Inc.
Jul 22, 2026, 11:01 ET Sony FX5 5K Cinema Camera Announced - First Look YouTube Video at B&H Photo Video
https://www.bhphotovideo.com/c/product/1989701-REG/sony_ilmefx5bb_fx5_cinema_camera.htmlProduct Highlights:5K 16.6MP Stacked Full-Frame Sensor 5K60
More news about: B&H Photo
Jul 22, 2026, 07:00 ET Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, BB Biotech, and other leading healthcare investors.The financing, based on current plans, extends Mentari's cash runway into 2029 and through Phase
More news about: Mentari Therapeutics
Jul 20, 2026, 08:00 ET Aqualis Partners Reunites Longtime Secondaries Team, Naming Hong Pan and Steve Talbot as Partners
spanning its buyout, growth equity, venture capital, and real assets and sustainability strategies. Talbot began his career in investment banking at BB&T Capital Markets, advising companies on mergers, acquisitions, and capital markets financings. He holds a B.S. in Business and Enterprise Management
More news about: Aqualis Partners
Jul 20, 2026, 03:00 ET Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jul 19, 2026, 06:30 ET ANAC Publishes Proposed Noise Certification Criteria for Eve 100
https://eve.imagerelay.com/fl/545b460810be4c698559bb0e836f6d6d About Eve Air MobilityEve Air Mobility is dedicated to accelerating the Urban Air Mobility
More news about: Eve Air Mobility
Jul 17, 2026, 11:50 ET AIP Capital and Monroe Capital Announce Closing of Inaugural $643 Million Aircraft Asset-Backed Securitization
be issued have an initial LTV of 87%.The Class A notes will be rated A, the Class B notes will be rated BBB and the Class C notes will be rated BB by DBRS Morningstar and Kroll Bond Rating Agency. Additionally, the Class A notes will be rated A2 by Moody's Investors Service.AIP Capital will
More news about: AIP Capital
Jul 17, 2026, 11:25 ET AIP Capital and Monroe Capital Announce Closing of Inaugural $643 Million Aircraft Asset-Backed Securitization
be issued have an initial LTV of 87%.The Class A notes will be rated A, the Class B notes will be rated BBB and the Class C notes will be rated BB by DBRS Morningstar and Kroll Bond Rating Agency. Additionally, the Class A notes will be rated A2 by Moody's Investors Service.AIP Capital will
More news about: AIP Capital
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic
More news about: Leads Biolabs
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic
More news about: Nanjing Leads Biolabs Co., Ltd.